WB | 1/1000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | Mediator of RNA polymerase II transcription subunit 19, Lung cancer metastasis-related protein 1, Mediator complex subunit 19, MED19, LCMR1 |
Entrez GeneID | 219541 |
WB Predicted band size | 26.3kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | This MED19 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 161-188 amino acids from the C-terminal region of human MED19. |
Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MED19抗体的3篇参考文献及其摘要概括:
1. **文献名称**: "MED19 promotes prostate cancer progression by enhancing AR signaling"
**作者**: Smith J, et al.
**摘要**: 研究通过免疫沉淀和Western blot技术发现MED19在前列腺癌中高表达,并通过与雄激素受体(AR)互作促进肿瘤生长。抗体实验证实其调控AR靶基因转录,影响癌细胞增殖。
2. **文献名称**: "MED19 knockdown suppresses lung cancer metastasis via inhibition of EMT"
**作者**: Li X, et al.
**摘要**: 利用MED19特异性抗体进行功能研究,发现抑制MED19可降低肺癌细胞侵袭能力,并逆转上皮间质转化(EMT)过程,提示其在转移中的关键作用。
3. **文献名称**: "The role of MED19 in breast cancer stem cell maintenance"
**作者**: Wang Y, et al.
**摘要**: 通过免疫组化分析显示MED19在乳腺癌干细胞中高表达,抗体介导的基因沉默导致干细胞特性丧失,证实其通过调控Wnt/β-catenin通路维持肿瘤干细胞自我更新。
注:以上文献为示例性质,实际引用时需根据具体论文内容调整,建议通过PubMed或学术数据库核实最新研究。
MED19 (Mediator Complex Subunit 19) is a component of the Mediator complex, a multi-protein assembly that regulates RNA polymerase II-dependent transcription. This complex acts as a molecular bridge, facilitating communication between transcription factors and the basal transcriptional machinery. MED19 plays a critical role in modulating gene expression by influencing chromatin structure and recruiting transcriptional coactivators. Structurally, it contains conserved domains that mediate interactions with other Mediator subunits and transcriptional regulators.
Research highlights MED19's involvement in cellular processes such as proliferation, differentiation, and apoptosis. Dysregulation of MED19 has been linked to cancer progression, particularly in prostate, breast, and liver cancers, where its overexpression correlates with tumor growth, metastasis, and poor prognosis. Studies suggest it may promote oncogenesis by enhancing the transcription of genes involved in cell cycle control and survival pathways.
MED19-specific antibodies are essential tools for investigating its biological functions and mechanisms. They enable detection and quantification of MED19 protein levels in tissues or cells via techniques like Western blot, immunohistochemistry, and immunofluorescence. These antibodies also support chromatin immunoprecipitation (ChIP) assays to map MED19-DNA interactions or study its association with transcriptional complexes. Recent therapeutic explorations target MED19 in cancer, with antibody-based strategies aiming to disrupt its oncogenic interactions. However, its precise regulatory roles and therapeutic potential require further validation in diverse models.
×